<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391935</url>
  </required_header>
  <id_info>
    <org_study_id>RCS-01-001-2014</org_study_id>
    <nct_id>NCT02391935</nct_id>
  </id_info>
  <brief_title>Study of Intradermal Injections of RCS-01 in Male and Female Subjects</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RepliCel Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JensonR+ Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PHARMALOG Institut f端r klinische Forschung GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syreon Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovacell Biotechnologie AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datinf GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RepliCel Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety profile of RCS-01 injections as
      compared to placebo injections. This study will also measure the impact these injections will
      have on skin markers related to aging through evaluation of gene expression profiles.

      30 participants will be selected for this study based on their health status, current/past
      medications, and ability to adhere to protocol-related requirements. At the first visit and
      after providing informed consent, participants are evaluated against the study
      inclusion/exclusion criteria and provide blood samples for screening assessments (including
      virology). If suitable for study participation, participants will provide a biopsy from the
      scalp from which RCS-01 will be prepared and will have four treatment evaluation sites
      identified on their buttocks, two on each side.

      Study participants will be randomized to one of two treatment subgroups. Participants in the
      RCS-01 Subgroup (n=24) will receive injections of RCS-01 or placebo or a 'sham' injection (a
      needle penetration without injection of liquid). Participants in the the Placebo Subgroup (n=
      6) will be randomized to receive only injections of placebo or sham injections.

      Baseline evaluations of subjects' overall health and skin condition at treatment sites on
      their buttocks will be performed before receipt of injections at Day 0. In addition to
      injections delivered at Day 0, the pre-selected treatment evaluation sites will receive
      intradermal injections of RCS-01 or placebo (cryomedium) or a sham injection four (4) and
      eight (8) weeks after Day 0 according to a randomization schedule for a total of three (3)
      injections per treatment site.

      All participants will return to the clinic for at least 9 visits during the 52-week follow-up
      period to monitor long-term safety. At the 12-week time point, 18 randomly-selected
      participants from the RCS-01 Subgroup will provide biopsies from all injection sites for
      analysis of skin markers related to aging. At the 26-week time point, the remaining
      participants will provide biopsies of all injection sites for histopathological analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2015</start_date>
  <completion_date type="Actual">July 12, 2017</completion_date>
  <primary_completion_date type="Actual">July 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of local adverse events</measure>
    <time_frame>52 weeks after first injection</time_frame>
    <description>Within-patient comparison of the local (reported at treatment evaluation sites) adverse event profile between treatment evaluation sites treated with RCS-01 or placebo. The local adverse event profile is defined by the incidence, relationship to treatment, severity and seriousness of adverse events reported at the treatment evaluation sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>52 weeks after first injection</time_frame>
    <description>Between-subject comparison of the systemic (not reported at treatment evaluation sites) adverse event profile between participants in the RCS-01 Subgroup versus Placebo Subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormalities in skin structure</measure>
    <time_frame>52 weeks after first injection</time_frame>
    <description>A within-patient and between patient comparison of histology results from analyses performed on biopsies obtained from treatment evaluation sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of changes in markers related to skin aging</measure>
    <time_frame>12 weeks after first injection</time_frame>
    <description>Markers to be assessed include fibrillar collagen type I (COL 1A1, COL 1A2) and type III (COL 3A1), transforming growth factor beta1, connective tissue growth factor, matrix metalloproteinases 1, 3 and 9, tissue inhibitor of matrix metalloproteinase 1 and lumican . Incidence of changes within- and between-participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Intrinsic Aging of Skin</condition>
  <condition>Skin Wrinkling</condition>
  <condition>Solar Degeneration of Skin</condition>
  <arm_group>
    <arm_group_label>RCS-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured, autologous hair follicle cells suspended in cryomedium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>cryomedium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RCS-01</intervention_name>
    <description>Cultured, autologous hair follicle cells suspended in cryomedium</description>
    <arm_group_label>RCS-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cryomedium</description>
    <arm_group_label>RCS-01</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>skin penetration of the needle without injection of liquid</description>
    <arm_group_label>RCS-01</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female Caucasian in good health between the age of 50 and 65 years.

          2. Female subjects must be post-menopausal for at least one year or surgically sterile.

          3. Signed and dated informed consent and willingness to attend all study visits and
             complete all procedures required by this protocol.

          4. The treatment evaluation sites are of uniform skin color without erythema, dark
             pigmentation or scars that may confound study results.

        Exclusion Criteria:

          1. Any transient skin disorder or infections (e.g. pyoderma, tinea corporis, contact or
             irritative dermatitis, scleroderma etc.) within 20 cm of the treatment evaluation
             sites or the presence of tattoos near the treatment sites.

          2. Subjects diagnosed with psoriasis, lichen planus, vitiligo, systemic scleroderma, or
             lupus erythematosus.

          3. Any condition that, in the investigator's opinion, would impact subject's safety
             and/or a subject's ability to complete all study related procedures.

          4. History of infection with or positive serology results for human immunodeficiency
             virus (HIV), hepatitis B or C, or syphilis.

          5. Presence/history of hypertrophic scars and/or keloids.

          6. Subjects diagnosed with cancer with or without chemotherapy treatment within 3 years
             prior enrollment.

          7. Women who are pregnant or nursing.

          8. Current use of any medications not permitted in the study

          9. Ongoing or recent participation in a cosmetic and/or clinical research study prior to
             enrolment.

         10. Subject not agreeing to avoid UV exposure (sun, solarium) on the nude buttocks during
             the study period.

         11. Known allergy or hypersensitivity to human serum albumin, DMSO, gentamicin, material
             of bovine origin and/or local anesthetics.

         12. Close affiliation with the investigational site (e.g., a close relative of the
             investigator or a possibly dependent person (e.g., employee or student of the
             investigational site)).

         13. Subjects diagnosed with coagulopathies or significant thrombocytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Marini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUF Leibniz-Institut f端r umweltmedizinische Forschung gGmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IUF Leibniz-Institut f端r umweltmedizinische Forschung gGmbH</name>
      <address>
        <city>D端sseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.replicel.com</url>
    <description>RepliCel Life Sciences, Inc. Website</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Effect of Ultraviolet Radiation on Normal Skin (Photo-aging)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

